Edition:
United States

Biopharmx Corp (BPCG.F)

BPCG.F on Frankfurt Stock Exchange

0.40EUR
22 Jun 2017
Change (% chg)

€0.01 (+3.59%)
Prev Close
€0.39
Open
€0.39
Day's High
€0.40
Day's Low
€0.39
Volume
0
Avg. Vol
--
52-wk High
€0.77
52-wk Low
€0.36

Select another date:

Tue, Jun 13 2017

BRIEF-BioPharmx Q1 non-GAAP loss per share $0.07 excluding items

* Q1 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S

BRIEF-Biopharmx says achieved primary endpoint in trial of treatment for acne

* Biopharmx Corp says achieved primary endpoint in its phase 2b clinical trial evaluating bpx-01

BRIEF-Biopharmx announces $5 million offering

* Biopharmx Corp says net proceeds of offering will be used to advance Biopharmx dermatology-focused drug delivery and clinical programs

BRIEF-BioPharmX completes last subject visit in its phase 2B trial of BPX-01, expects to report topline results first half of May

* BioPharmX completes last subject visit in its phase 2B trial of BPX-01, expects to report topline results first half of May 2017

BRIEF-Biopharmx AACR Poster will present findings

* Biopharmx AACR poster will present findings suggesting molecular iodine inhibits breast cancer cell growth and drives cancer cell death

BRIEF-Biopharmx Q4 non-gaap net loss $4.4 mln, or $0.08/shr

* Biopharmx reports fourth quarter and full year 2017 financial results

BRIEF-BioPharmX to share scientific data which will suggest promise of BPX-01 as topical acne therapy

* Biopharmx Corp - will share scientific data, which will suggest BPX-01 delivers acne-fighting medication to target area safely without systemic side effects Source text for Eikon: Further company coverage:

BRIEF-Biopharmx board authorizes increase in number of board members from three to four

* On Jan 17, board authorized an increase in number of members of board from three to four - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Specialty pharma industry veteran Charles Gregory Vontz joins Biopharmx board

* Specialty pharma industry veteran Charles Gregory Vontz joins Biopharmx board

Select another date:

More From Around the Web